The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis

Authors

  • Y.-C. Huang,

    1. Department of Dermatology, Wan Fang Hospital, Taipei Medical University, 111 Xinglong Road Section 3, Wenshan District, Taipei City 116, Taiwan
    Search for more papers by this author
  • Y.-C. Li,

    1. Department of Dermatology, Wan Fang Hospital, Taipei Medical University, 111 Xinglong Road Section 3, Wenshan District, Taipei City 116, Taiwan
    Search for more papers by this author
  • T.-J. Chen

    1. Department of Dermatology, Wan Fang Hospital, Taipei Medical University, 111 Xinglong Road Section 3, Wenshan District, Taipei City 116, Taiwan
    2. Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
    Search for more papers by this author

  • Funding sources
    None.

  • Conflicts of interest
    None declared.

Ting-Jui Chen.
E-mail: paladerm@yahoo.com.tw

Summary

Background  Quantitative analysis of intravenous immunoglobulin (IVIg) treatment against toxic epidermal necrolysis (TEN) is lacking.

Objectives  To provide a meta-analysis evidence-based examination of IVIg efficacy against TEN.

Methods  A systematic review and meta-analysis of literature published before 31 July 2011 was conducted. In observational controlled studies with at least eight patients with TEN receiving IVIg treatment, a pooled estimate of mortality risk was determined, comparing IVIg and supportive care. Statistical analyses were performed on raw data to compare the clinical differences between (i) high-dose and low-dose IVIg treatment in adult patients and (ii) paediatric and adult patients treated with IVIg.

Results  Seventeen studies met inclusion criteria. Overall mortality rate of patients with TEN treated with IVIg was 19·9%. The pooled odds ratio (OR) for mortality from six observational controlled studies comparing IVIg and supportive care was 1·00 [95% confidence interval (CI) 0·58–1·75; = 0·99]. The pooled OR for mortality in patients treated with high-dose IVIg vs. supportive care was 0·63 (95% CI 0·27–1·44; = 0·27). Adults treated with high-dose IVIg exhibited significantly lower mortality than those treated with low-dose IVIg (18·9% vs. 50%, respectively; = 0·022); however, multivariate logistic regression model adjustment indicated that IVIg dose does not correlate with mortality (high vs. low dose: OR 0·494; 95% CI 0·106–2·300; = 0·369). Paediatric patients treated with IVIg had significantly lower mortality than adults (0% vs. 21·6%; = 0·001).

Conclusions  Although high-dose IVIg exhibited a trend towards improved mortality and children treated with IVIg had a good prognosis, the evidence does not support a clinical benefit of IVIg. Randomized controlled trials are necessary.

Ancillary